मैट्रिक्स
 
 
स्मिथक्लाइन फार्मा > कंपनी इतिहास > Pharmaceuticals > कंपनी इतिहास का स्मिथक्लाइन फार्मा - बीएसई: 500647, NSE: SMITHKLPHA

स्मिथक्लाइन फार्मा

बीएसई: 500647  |  NSE: SMITHKLPHA  |  ISIN: INE266A01019  |  Pharmaceuticals

कंपनी इतिहास - स्मिथक्लाइन फार्मा
1984
 
 - The company was incorporated on 11th April, as a private limited
 company under the name and style of `Eskayef private limited' to
 acquire by purchase, amalgamation or otherwise the business of the
 Indian branch of Eskaylab Limited, a company incorporated in
 England.
 
 - The main objects and activities of the company include the
 manufacture of human and veterinary pharmaceuticals, bulk drugs skin
 care products, veterinary feed supplements and marketing of
 bio-analytical and diagnostic instruments.
 
 1985
 
 - the company was converted into a public limited company on 11th
 March.
 
 - In term of the Scheme of Amalgamation sanctioned by the High Court
 of
 Karnataka at Bangalore by its order dated 11th February, the
 undertaking in India of Eskaylab limited, U.K. was vested in the
 company with effect from the commencement of business on 1st
 December,
 1983 for a consideration of Rs. 9 crore.
 
 - User common licence agreements dated 6th March, were entered into
 between Smith Kline & French Laboratories Ltd., U.K. and the Company
 under which Smith Kline & French granted to the Company exclusive
 right
 to use certain trade marks.
 
 - Smith Kline Beckman Corporation would make available to the
 Company,
 technical know-how and the results of R & D appropriate to Indian
 conditions.
 
 - 2 shares subscribed for by the signatories to the Memorandum of
 Association.  19,99,998 shares allotted without payment in cash to
 Eskaylab Ltd., U.K. as part consideration for the transfer of the
 business to the Company.  30,00,000 No. of equity shares issued
 (prem.
 Rs 8 per share) out of which 4,50,000 shares to financial
 institutions,
 2,50,000 shares to resident Indian employees and 1,00,000 shares to
 Indian business associates were reserved and allotted on a firm
 basis.
 The balance 22,00,000 shares were offered for public subscription
 during April.
 
 1986
 
 - Six new pharmaceutical products were introduced.
 
 1987
 
 - The Company received permission to manufacture Beckman Scientific
 &
 Research instruments such as High Pressure Liquid Chromatography
 (HAPLY), spectrophotometers, etc., and hopes to commence the
 manufacture of Hapless before the end of 1988.
 
 - The Company also applied for an industrial license to manufacture
 of
 Penicillin-G.  The company introduced in the market a range of
 disposable syringes under the brand name SAFE AID during 1987-89.
 
 - The Company proposed to put up a plant at Mysore for manufacture of
 6
 APA and several semi-synthetic-penicillin's.
 
 - The Company has a research centre at Bangalore which carries out
 fundamental research and is also equipped for carrying out
 pharmaceutical and analytical development work.  It also has a
 chemical
 development laboratory for developing processes for the manufacture
 of
 bulk drugs and intermediates.
 
 - Four new pharmaceutical products, viz., `Ridaura' a disease
 modifying
 oral gold capsules for the treatment of rheumatrod arthritis;
 `Ecomint', an enteric coated soft gelatin capsule for irritable bowl
 syndrome; `Dizec', a digestive enzyme and `Histryl, an antihistamine
 in
 sustained release for allergic disorders, were introduced.
 
 - In the annual health care market, the Company introduced
 `Visorben'
 for pests.  Furacin-Vet solution for intrauterin infections in
 cattle,
 `Valbazen' suspension as anthelmentic and `Nutrilay' a vitamin &
 mineral combination exclusively formulated for poultry and `Dizec'
 liquid were well accepted in the market.
 
 - 25,00,000 bonus shares issued in proportion 1:2.
 
 1991
 
 - The Company introduced two new products, viz., Disfect-S, a
 disinfectant and Nutrical a feed supplement, both in the animal care
 area.
 
 - 30,00,000 bonus equity shares issued in prop. 2:5.
 
 1992
 
 - During the year, the company introduced new products viz.,
 `Fefol-2',
 a sustained-release haematinic preparation, Frusemene-40, an
 extension
 of the existing product for the treatment of congestive cardiac
 failure
 and Amoxisol, a water soluable amoxycillin for veterinary use.
 
 - The Company undertook to set up a multipurpose chemical plant on a
 16
 acre site in an industrial suburb of Mysore, a Centrally declared
 backward area, to manufacture several high technology bulk drugs
 including Cimetidine and Albendazole used in the treatment of peptic
 ulcer and worm infestations.
 
 1994
 
 - With effect from 13th July, the name of the Company was changed
 from
 Eskayef Ltd. to Smithkline Beecham Pharmaceuticals (India) Limited.
 
 - 42,00,000 bonus equity shares issued in prop. 2:5.
 
 1995
 
 - The Company's Research & Development activities continue to be
 directed towards upgradation of technology, development of new
 products
 in the area of Human Healthcare.
 
 - The Company has also entered into an agreement with Pfizer on
 January
 20th, for manufacturing Pfizer's sertain Animal Healthcare products
 on
 its behalf and selling those to Pfizer as non-exclusive agent for
 the
 year January 1 to December 31st, against reimbursement of
 manufacturing
 costs etc. as may be mutually agreed.
 
 1996
 
 - During the year celebrated as the Silver Jubilee Year for the
 Bangalore facility.  It was 25 years ago when the Company shifted
 from
 Mumbai to Bangalore to set up one of the first major pharmaceutical
 units in the State of Karnataka.
 
 - The Company's Research & Development activities continue to be
 directed towards upgradation of technology and development of new
 products in the area of Human Healthcare.
 
 1997
 
 - Pune based Serum Institute and SmithKline Beecham have entered into
 a
 collaboration for joint development and distribution of paediatric
 combination vaccines in India.
 
 - SmithKline Beecham obtained approval from FIPB in September 1995
 to
 set up a wholly-owned subsidiary.
 
 - As a result of the takeover of the animal health care division of
 SmithKline Beecham by Pfizer, SBP has entered into a non-compete
 agreement with Pfizer.
 
 1998
 
 - International drug major SmithKline Beecham has signed a 0,000
 contract with the Hyderabad-based Indian Institute of Chemical
 Technology (IICT) to do frontline research in medicinal chemistry.
 
 - SmithKline Beecham Pharmaceuticals India (SBPI) has reached an
 agreement with Indian Institute of Chemical Research (IICR),
 Hyderabad
 to form a research and development (R&D) centre in the country.
 
 - SBPI has two manufacturing facilities in the country, a
 formulation
 plant at Bangalore (which includes a state-of-the-art facility for
 Iodex) and a multi-purpose bulk drug unit at Mysore, both of which
 are
 ISO 9002 certified.
 
 - SmithKline Beecham has also recently entered into a memorandum of
 understanding with the Indian Institute of Chemical Technology of
 Hyderabad to expand R&D.
 
 - SmithKline Beecham, the U.K. based major pharmaceutical company,
 has
 forged a collaboration of Chemical Technology, in the area of
 medicinal
 chemistry.
 
 - The Company has introduced a money back guarantee on its Iodex
 Power
 Cream - The company is also entering into a co-marketing agreement
 with
 Glaxo for the products.
 
 1999
 
 - Pharma multinational SmithKline Beecham Pharmaceuticals is
 considering options for a DPT-hepatitis-B combination vaccine after
 its
 agreement with Pune-based Serum Institute fell through.
 
 - SmithKline Beecham Pharmaceuticals (India) Ltd (SBPL) has decided
 to
 bring the company's entire worldwide clinical data processing under
 one
 umbrella in Bangalore.
 
 - The company has two manufacturing units in the country.  One is a
 formulation plant in Bangalore, and the other, a bulkdrug unit in
 Mysore.
 
 2000
 
 - Moody's Investors Service (Moody's) has put Glaxo Wellcome's AA2
 rating under review, for a possible downgrade.  At the same time, it
 has placed Smithkline Beecham's AA3 rating under review, for a
 possible
 upgrade.  The review has been promoted by the announcement of a
 merger
 agreement between Glaxo Wellcome and SmithKline Beecham.
 
 - SmithKline Beecham Biologicals, a part of Pharma major SmithKline
 Beecham, has launched a Web site on vaccination and vaccine
 preventable
 diseases.
 
 - Mr. Paul Roache resigned as Chairman and Mr. P. Murari and Mr. 
 T.R.
 Satish Chandran were appointed as Additional Directors.
 
 - SmithKline Beecham has launched jaljeera-flavoured ENO antacid.
 
 - SmithKline Beecham Pharmaceuticals has introduced a money-back
 guarantee on Iodex Power Cream, a multi-purpose cream effective for
 most muscular pains.
 
 - Smithkline Beecham sold rights to key drugs to Roche and Novartis
 for
 a total net consideration of .46bn to smooth its merger with Glaxo
 Wellcome.
 
 - Mr. Mukund Srinath has resigned as Senior Manager-Legal and
 Company
 Security with effect from 1st November.
 
 2001
 
 - Mr Venkatraman Thyagarajan has been appointed as the managing
 director effective from 22nd January for a period of five years.
स्रोत: रेलीगरे टेचनोवा

न्यूज़ फ़्लैश

  • BREAKING NEWS RED : हरियाणा में शाम 6 बजे तक 62.14% मतदान
  • BREAKING NEWS RED : महाराष्ट्र में शाम 6 बजे तक 55.58% मतदान
  • ELECTION FLASH : हरियाणा में BJP का क्लीन स्वीप
  • ELECTION FLASH : हरियाणा:BJP को तीन चौथाई सीट मिलने की उम्मीद
  • ELECTION FLASH : हरियाणा: BJP-75 सीट, कांग्रेस-10 सीट
  • ELECTION FLASH : हरियाणा: INLD-0, अकाली दल-1 सीट
  • ELECTION FLASH : हरियाणा: JJP-2 सीट, अन्य-2 सीट
  • ELECTION FLASH : महाराष्ट्र: BJP-सेना गठबंधन की जबरदस्त जीत
  • ELECTION FLASH : BJP-शिवसेना को 243 सीटें मिलने की उम्मीद
  • ELECTION FLASH : महाराष्ट्र:BJP-141 सीट, शिवसेना-102 सीट

अभी देखें

ओवरड्राइव

OUR WINNING PICKS

DID YOU INVEST?

INTRADAY PICKS!

(August 06, 2018)

AT (Rs)



GAIN (Rs)

ALL TIME WINNERS

RECO PRICE

PEAK PRICE

OUR PACKAGES

Super Combo

Powerful mix of both trader and investor packs with timely expert advice.

Technical

Designed especially for traders looking to tap the profit opportunities of volatile markets.

Fundamental

For all investors looking to unearth stocks that are poised to move.